Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Transition Therapeutics says Alzheimer’s drug effective in sub-group

Drug developer Transition Therapeutics Inc said its experimental drug reduced severe agitation and aggression in Alzheimer’s patients, citing data from a large study. The company said on Thursday that it would use the data to discuss a potential late-stage trial of the drug, ELND005, with the U.S. Food and Drug Administration. The company said in […]

Read More »

Germany’s Merck KGaA scraps unit brands

Germany’s Merck KGaA said it would scrap its divisional brands Merck Serono and Merck Millipore and do business simply as Merck outside North America. In the United States and Canada, where its U.S. namesake Merck & Co Inc holds the rights to the Merck name, the German company will continue to operate as EMD Serono […]

Read More »

GSK Receives Approval for BREO ELLIPTA for the Treatment of Adults With Asthma

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA–(Marketwired – Aug 6, 2015) – GSK (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) announce the approval in Canada of BREO® ELLIPTA® (fluticasone furoate/vilanterol dry powder for oral inhalation) for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. BREO® […]

Read More »

Theravance Biopharma Announces Health Canada Approval for VIBATIV (telavancin) for Treatment of HAP/VAP Caused by Gram-Positive Bacteria, Including MRSA

Latest Approval Expands Product Label in Canada and Further Strengthens Global Brand for Once-Daily, Dual Mechanism Antibiotic DUBLIN, IRELAND–(Marketwired – Jul 23, 2015) – Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today announced that Health Canada has approved VIBATIV® (telavancin) for the treatment of adult patients with hospital-acquired bacterial pneumonia (HAP) and […]

Read More »

Impact of Improved Data Protection on Health Costs in Canada and Japan: Lessons for the Trans-Pacific Partnership (TPP)

TORONTO, ON–(Marketwired – July 20, 2015) – New research published by the Canadian Health Policy Institute (CHPI) suggests fears that the Trans-Pacific Partnership (TPP) will drive up health costs are unfounded. Critics argue provisions in the international trade deal that improve regulatory data protection (RDP) for new drugs could increase spending on health care. The […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom